The national economic burden of rare disease in the United States in 2019

BACKGROUND: To provide a comprehensive assessment of the total economic burden of rare diseases (RD) in the United States (U.S.) in 2019. We followed a prevalence-based approach that combined the prevalence of 379 RDs with the per-person direct medical and indirect costs, to derive the national econ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Grace, Cintina, Inna, Pariser, Anne, Oehrlein, Elisabeth, Sullivan, Jamie, Kennedy, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004040/
https://www.ncbi.nlm.nih.gov/pubmed/35414039
http://dx.doi.org/10.1186/s13023-022-02299-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004040/
https://www.ncbi.nlm.nih.gov/pubmed/35414039
http://dx.doi.org/10.1186/s13023-022-02299-5

Ejemplares similares